InFocus Capital Partners

Visibly, Inc. is a healthcare technology company based in Chicago, Illinois, that specializes in online eye examination services for patients across the United States. Originally known as Opternative, Inc., the company rebranded in November 2018. Visibly offers a refractive eye exam to measure prescriptions for glasses and contact lenses, providing a digital solution for vision care. Its products cater to a variety of sectors, including e-commerce employers, eye care providers, insurance companies, online healthcare platforms, and optical retail. By offering a virtual vision testing technology, Visibly ensures that patients can conveniently renew their prescriptions and address their eye health needs from anywhere at any time, enhancing accessibility to essential eye care services.

Re-Vana Therapeutics Ltd is a company based in Belfast, United Kingdom, specializing in ocular pharmaceuticals and drug delivery systems. Founded in 2016, it focuses on developing biodegradable drug delivery platforms that target chronic eye diseases, including age-related macular degeneration, diabetic retinopathy, glaucoma, and uveitis. The company offers two primary product platforms: OcuLief, designed for the long-term release of treatments for age-related macular degeneration and diabetic retinopathy, and EyeLief, aimed at delivering therapeutics for glaucoma and retinal diseases. These platforms utilize FDA-approved polymers and enable the controlled release of a variety of therapeutic molecules over periods ranging from one week to a year. Re-Vana’s approach enhances patient compliance by minimizing pain and the frequency of treatments, while also aiming to reduce side effects and healthcare costs.

Stuart Therapeutics is a biotechnology company focused on developing PolyCol, a therapeutic platform designed for various ophthalmic conditions. This innovative platform utilizes a synthesized peptide to repair disease-damaged helical collagen in the eye, promoting accelerated healing of epithelial cells, restoring nerve function, and reducing inflammation. PolyCol addresses several ophthalmic indications, including dry eye disease, dry age-related macular degeneration, and glaucoma. The technology is rooted in patented research from a prominent U.S. university and is supported by additional intellectual property acquired by the company. In addition to ophthalmic applications, Stuart Therapeutics is exploring the use of PolyCol for gastrointestinal, inflammatory, and oncology conditions, aiming to provide new treatment options across a range of medical fields.

ONL Therapeutics is a biopharmaceutical company focused on developing innovative therapeutics to protect and improve vision in patients with retinal diseases and conditions. Founded in 2006 and headquartered in Ann Arbor, Michigan, the company specializes in creating photoreceptor protective agents that target the FAS apoptotic pathway. Its drug programs aim to safeguard photoreceptors, thereby enhancing outcomes for patients undergoing surgeries related to retinal detachment and other serious vision-threatening issues. Through its research and development efforts, ONL Therapeutics seeks to provide effective solutions for preserving sight and improving the quality of life for individuals affected by these conditions.

Re-Vana Therapeutics Ltd is a company based in Belfast, United Kingdom, specializing in ocular pharmaceuticals and drug delivery systems. Founded in 2016, it focuses on developing biodegradable drug delivery platforms that target chronic eye diseases, including age-related macular degeneration, diabetic retinopathy, glaucoma, and uveitis. The company offers two primary product platforms: OcuLief, designed for the long-term release of treatments for age-related macular degeneration and diabetic retinopathy, and EyeLief, aimed at delivering therapeutics for glaucoma and retinal diseases. These platforms utilize FDA-approved polymers and enable the controlled release of a variety of therapeutic molecules over periods ranging from one week to a year. Re-Vana’s approach enhances patient compliance by minimizing pain and the frequency of treatments, while also aiming to reduce side effects and healthcare costs.

Mojo Vision Inc. is a company based in Saratoga, California, established in 2015, that specializes in augmented reality technology. The firm is focused on developing high-performance micro-LED displays for various applications, including consumer, enterprise, and government sectors. It has created the world's smallest and densest dynamic display integrated into a smart contact lens, designed to provide users with timely information without disrupting their focus. This innovative product allows for hands-free connectivity and access to relevant information, thereby minimizing reliance on traditional mobile devices. Additionally, Mojo Vision has formed a joint development agreement with Menicon Co., Ltd. to explore smart contact lens products further, leveraging its advanced micro-LED technology and manufacturing processes to disrupt the display industry.

ONL Therapeutics is a biopharmaceutical company focused on developing innovative therapeutics to protect and improve vision in patients with retinal diseases and conditions. Founded in 2006 and headquartered in Ann Arbor, Michigan, the company specializes in creating photoreceptor protective agents that target the FAS apoptotic pathway. Its drug programs aim to safeguard photoreceptors, thereby enhancing outcomes for patients undergoing surgeries related to retinal detachment and other serious vision-threatening issues. Through its research and development efforts, ONL Therapeutics seeks to provide effective solutions for preserving sight and improving the quality of life for individuals affected by these conditions.

Trefoil Therapeutics is a biotechnology company dedicated to developing innovative treatments for endothelial cell-mediated diseases, particularly focusing on corneal conditions such as Fuchs dystrophy. Utilizing its engineered fibroblast growth factor-1 (FGF-1) technology platform, Trefoil aims to create first-in-class regenerative pharmacologic therapies to address serious ophthalmic diseases that can lead to preventable blindness. The company is currently advancing a topical eye drop formulation, TTHX1114, designed to treat ulcerative conditions affecting the cornea, which can result in corneal scarring and significant vision loss. With a management team possessing over 100 years of combined experience in pharmaceutical development and commercialization, Trefoil is committed to improving human health through protein-engineered therapies. The company has gained recognition within the biopharmaceutical community, receiving accolades from programs such as the CONNECT Springboard business plan competition and the Southeast Biotechnology Early Company Competition.

Pr3vent, Inc. is a technology company based in Palo Alto, California, that specializes in developing artificial intelligence and machine learning solutions for screening ophthalmic conditions in newborns. Founded in 2017, Pr3vent's innovative approach includes using a wide-angle fundus camera to capture images of the entire back of the eye, allowing for comprehensive newborn eye screenings. Their algorithms analyze these non-invasive images to detect abnormalities in the retina, providing instant recommendations for further examination and treatment when necessary. By offering affordable expert exams at birth, Pr3vent aims to facilitate early intervention and reduce the risk of preventable vision loss in infants, thereby improving overall pediatric eye care.

IACTA Pharmaceuticals is focused on developing innovative eyecare products aimed at treating diseases and enhancing patient outcomes. The company specializes in a hydrophobic drug designed for encapsulation and delivery to ocular tissues, which facilitates effective treatment for conditions such as dry eye. IACTA Pharmaceuticals emphasizes the importance of collaboration among business partners, scientists, and the community, recognizing that the success of a pharmaceutical venture involves not only scientific advancements but also the contributions of individuals and families affected by health issues.

Qura, Inc. is a company based in Framingham, Massachusetts, that specializes in the development of micro-injectable implants and ultra-miniature implantable devices designed to monitor physiological pressure changes. Founded in 2013, Qura aims to revolutionize physiologic monitoring in biomedicine by creating a series of networked tools that communicate in real-time to monitor diseases and administer timely treatments. One of its key innovations is a wireless implantable pressure sensor that continuously measures and monitors ocular health, particularly for conditions like glaucoma. By providing healthcare providers with real-time data, Qura's technologies have the potential to improve patient outcomes and reduce treatment costs, thereby transforming both research capabilities and clinical care.

Alievio, Inc. is an innovative medical device company based in Research Triangle Park, North Carolina, focused on developing solutions for glaucoma patients. The company has introduced Sollevio, a novel noninvasive device designed for the titration of postoperative intraocular pressure in individuals with refractory glaucoma. This device aims to address the complications commonly associated with traditional glaucoma surgeries and offers ophthalmologists a new tool to halt the progression of the disease. Founded in 2010 and originally known as Camras Vision, Inc., Alievio rebranded in June 2019 to reflect its commitment to advancing glaucoma treatment.

Trefoil Therapeutics is a biotechnology company dedicated to developing innovative treatments for endothelial cell-mediated diseases, particularly focusing on corneal conditions such as Fuchs dystrophy. Utilizing its engineered fibroblast growth factor-1 (FGF-1) technology platform, Trefoil aims to create first-in-class regenerative pharmacologic therapies to address serious ophthalmic diseases that can lead to preventable blindness. The company is currently advancing a topical eye drop formulation, TTHX1114, designed to treat ulcerative conditions affecting the cornea, which can result in corneal scarring and significant vision loss. With a management team possessing over 100 years of combined experience in pharmaceutical development and commercialization, Trefoil is committed to improving human health through protein-engineered therapies. The company has gained recognition within the biopharmaceutical community, receiving accolades from programs such as the CONNECT Springboard business plan competition and the Southeast Biotechnology Early Company Competition.